Contact information
daniel.prietoalhambra@ndorms.ox.ac.uk
Mahkameh Mafi
mahkameh.mafi@ndorms.ox.ac.uk
Research groups
Websites
-
Athena SWAN
Self assessment-team
- European Health Data & Evidence Network (EHDEN)
- EU ADR Alliance
- International Society of Pharmacoepidemiology (ISPE)
-
National Institute for Health Research (NIHR)
Faculty (NIHR Clinician Scientist)
- Observational Health Data Sciences and Informatics (OHDSI)
-
SIDIAP Database
International Coordinator
- Erasmus MC University - Medical Informatics
Dani Prieto-Alhambra
MD MSc(Oxf) PhD
Professor of Pharmaco- and Device Epidemiology
- Section Head, Health Data Sciences, Botnar Institute for Musculoskeletal Science
- NIHR Senior Research Fellow
- Fellow of the International Society of Pharmaco-Epidemiology, FISPE
Real World Evidence, Pharmaco-epidemiology, Device Epidemiology
I am an epidemiologist and academic clinician scientist using routinely collected (real world) health data to generate reliable evidence for improved patient care.
I am interested in the use of large routinely collected health data (also known as real world data) to generate new knowledge or evidence on the utilisation, safety, and effectiveness of drugs and devices as used in usual practice conditions.
I lead the Health Data Sciences section at the Botnar Institute, a team of over 40 staff and students with extensive expertise in the curation and analysis of multiple real world data assets using the OMOP Common Data Model.
More recently, I have joined the European Health Data & Evidence Network EHDEN (www.ehden.eu) and the Observational Health Data Sciences and Informatics OHDSI (www.ohdsi.org) in an effort to accelerate and improve the quality of real world evidence internationally.
From February 2022, I am Deputy Director for the European Medicines Agency's Data Analysis and Real World Interrogation Network (DARWIN EU) Coordination Centre, and lead the Development pillar for the generation and/or validation of analytical tools to generate real world evidence for regulatory use.
Recent publications
Comorbidities, medication use, and overall survival in eight cancers: a multinational cohort study of 1.7 million patients across Europe.
Journal article
López-Sánchez I. et al, (2026), Lancet Reg Health Eur, 63
Implementation of OMOP and ConcePTION Common Data Models in CPRD GOLD: Risk of Bleeding and Cardiovascular Outcomes From Anticoagulant Use.
Journal article
Hunt NB. et al, (2026), Clin Pharmacol Ther
Data Resource Profile: Prostate cancer data from Clinical Practice Research Datalink linked hospital records, mortality data and cancer registry standardized to the Observational Medical Outcomes Partnership common data model (CPRD-PCa-OMOP).
Journal article
Tan EH. et al, (2026), Int J Epidemiol, 55
Incidence and survival of head and neck cancers in the United Kingdom 2000-2021.
Journal article
Miquel-Dominguez A. et al, (2026), Cancer Epidemiol, 101
Trends in use of Attention-Deficit Hyperactivity Disorder medications among children and adults in five European countries, 2010 to 2023: a population-based observational study.
Journal article
Li X. et al, (2026), Lancet Reg Health Eur, 61
dvancing pharmacogenomics in medicines regulation and clinical practice: a call for collaborative action.
Journal article
Gratton J. et al, (2026), Nat Rev Drug Discov, 25, 79 - 80
The risk of surgical site infection, septic arthritis, and osteomyelitis after hand trauma surgery.
Journal article
Wormald JCR. et al, (2026), Bone Joint J, 108-B, 96 - 102
Incidence and Survival of Colorectal Cancer in the United Kingdom From 2000 to 2021: A Population-Based Cohort Study.
Journal article
Pedregal-Pascual P. et al, (2025), Am J Gastroenterol, 120, 2909 - 2917
Phosphodiesterase-5 Inhibition and Alzheimer's Disease Risk: A Mendelian Randomisation Study.
Journal article
Alcalde-Herraiz M. et al, (2025), Aging Cell, 24
Diagnosis, Prognosis, and Drug Target Discovery for Chronic Widespread Pain: A Large Proteogenomic Study.
Journal article
Chen L. et al, (2025), Adv Sci (Weinh), 12